• ქართული
  • English
  • GSK buys U.S. cancer drugmaker Tesaro for hefty $5.1 billion

    GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, marking a major biotech investment by Chief Executive Emma Walmsley as she seeks to rebuild the group’s pharmaceuticals business.

    Market Quotes by TradingView